Trial reportNature immunology2020
Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes.
Open access · greenAbstract readClinical Trial
In one paragraph
Trial report in Nature immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 90 citations in OpenAlex.
- Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.Nature medicine · 2024Trial
- First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers.BMC medicine · 2024Trial
- Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2022Trial
- Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.Diabetologia · 2026Article
- Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- BCL6 in T cells promotes type 1 diabetes by redirecting fates of insulin-autoreactive B lymphocytes.iScience · 2026Article
- New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026Review
- Advanced immunotherapy across diseases and the role of artificial intelligence: A review.Biomolecules & biomedicine · 2026Review
- Modulating immune response for the prevention and treatment of type 1 diabetes.Frontiers in immunology · 2026Review
- Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.Nature reviews. Rheumatology · 2025Review
- Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects.Diabetes/metabolism research and reviews · 2025Article
- Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding.Diabetes care · 2025Review
- Pharmacotherapeutic strategies to promote regulatory T cell function in autoimmunity.Current opinion in immunology · 2025Review
- The Frequency but not the Phenotype of Circulating Peripheral T Helper Cells is Increased at Later Stages of Progression to Type 1 Diabetes.European journal of immunology · 2025Article
- Type 1 Diabetes Depends on CD4-Driven Expression of the Transcriptional Repressor Bcl6.Diabetes · 2025Article
- Article
- Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling.Frontiers in immunology · 2025Review
- Occurrence and role of Tph cells in various renal diseases.Molecular medicine (Cambridge, Mass.) · 2024Review
- High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia.Science China. Life sciences · 2024Article
- Integrating Omics into Functional Biomarkers of Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byCirculating T2020
- Commented on by
Authors and funding
18 authors at 4 institutions in 3 countries.
Natalie M Edner *Institute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.ORCID http://orcid.org/0000-0003-2799-2890
Frank Heuts *Institute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Niclas ThomasInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Chun Jing WangInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Lina PetersoneInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.ORCID http://orcid.org/0000-0001-8571-9185
Rupert KenefeckInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Alexandros KogimtzisInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Vitalijs OvcinnikovsInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Ellen M RossInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Elisavet NtavliInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Yassin ElfakiInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.ORCID http://orcid.org/0000-0001-6628-3080
Martin EichmannDepartment of Immunobiology, King's College London, London, UK.ORCID http://orcid.org/0000-0002-8675-2822
Roman BaptistaDepartment of Immunobiology, King's College London, London, UK.
Philip AmberyLate-stage Development, Cardiovascular, Renal and Metabolism , BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Lutz JermutusResearch and Early Development, Cardiovascular, Renal and Metabolism , BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Mark PeakmanDepartment of Immunobiology, King's College London, London, UK.
Miranda RosenthalInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK.
Lucy S K WalkerInstitute of Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London, UK. lucy.walker@ucl.ac.uk.ORCID http://orcid.org/0000-0001-5986-5015
The Royal Free Hospital · GBKing's College London · GBAstraZeneca (Sweden) · SEAstraZeneca (United Kingdom) · GB
Funding
Type 1 Diabetes Trialnet: Operations Coord. CenterU01DK061055 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI LACHIN, JOHN M · 2001 to 2008
$93.2MNorthwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3MType I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5MUCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1MPrediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5MType 1 Diabetes TrialNet: Support FacilitiesU01DK061041 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SKYLER, JAY S · 2001 to 2007
$6.1MTrialNet: University of Florida Clinical Center and NetworkU01DK085461 · NIDDK · UNIVERSITY OF FLORIDA · PI HALLER, MICHAEL JAMES · 2009 to 2018
$5.9MTrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8MType 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1DU01DK085499 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BAIDAL, DAVID · 2009 to 2018
$4.9MType 1 Diabetes TrialNet: Clinical Center at Yale University (U01)U01DK085466 · NIDDK · YALE UNIVERSITY · PI HEROLD, KEVAN C · 2009 to 2018
$3.3MType 1 Diabetes TrialNet at Indiana University Clinical CenterU01DK085505 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DIMEGLIO, LINDA A · 2009 to 2013
$3.0MType 1 Diabetes TrialNet: Clinical Centers (U01)U01DK085453 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI RASKIN, PHILIP · 2009 to 2013
$3.0MDiabetes UK 15/0005253Medical Research Council MR/N001435/1Medical Research Council MR/S009140/1NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061036NIDDK NIH HHS U01 DK061040NIDDK NIH HHS U01 DK061041NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061055NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085463NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085505NIDDK NIH HHS U01 DK085509
Abstract
Follicular helper T (T
Indexed as
AbataceptAnimalsBiomarkers, PharmacologicalCD28 AntigensCells, CulturedComputational BiologyDiabetes Mellitus, Type 1Disease Models, AnimalGerminal CenterHumansImmune Checkpoint InhibitorsImmunotherapyInducible T-Cell Co-Stimulator ProteinMiceMice, Inbred BALB CMice, KnockoutAbataceptBiomarkers, PharmacologicalCD28 AntigensIcos protein, mouseImmune Checkpoint InhibitorsInducible T-Cell Co-Stimulator Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.